The exon-skipping oligonucleotide, KitStop, depletes tissue-resident mast cells in vivo to ameliorate anaphylaxis.

Barry A. Hedgespeth,Douglas B. Snider, Katie J. Bitting,Glenn Cruse

Frontiers in immunology（2023）

引用 0|浏览6

暂无评分

摘要

KitStop treatment results in a significant reduction in systemic mast cell responses, thus offering the potential to serve as a powerful additional treatment modality for patients that suffer from anaphylaxis.

查看译文

关键词

KIT,anaphylaxis,exon skipping,mast cell (MC),mast cell depletion

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要